Despite advances in retinal imaging technology, patient disease activity can be missed in vision-threatening conditions. This oversight in everyday practice has the potential for undertreatment in patients. In addition, treatment delays further impact vision, worsening outcomes. Delays are in part due to a lack of awareness and urgency from the patient.
RetinAI’s Disease Evaluation Apps are accessed via Heidelberg AppWay. AppWay is a secure data transfer portal integrated in Heidelberg’s HEYEX 2. The Disease Apps provide expert-level analysis of a patient’s OCT volumes. Results are generated during the patient’s visit to complement evaluation and management of retinal diseases. The results can be used to better understand disease and status of biomarkers, and can provide valuable education and visualization of disease and biomarkers, empowering patients to be engaged in their disease management.
MEASURES TOTAL RETINAL AND LAYER THICKNESS FOR THE FOLLOWING LAYERS:
Retinal Nerve Fiber Layer (RNFL; Ganglion Cell Layer (GCL) + Inner Plexiform Layer (IPL); Inner Nuclear Layer (INL) + Outer Plexiform Layer (OPL); Outer Nuclear Layer (ONL); Photoreceptor (PR) + Retinal Pigment Epithelium (RPE; and Choriocapillaris (CC) + Choroidal Stroma (CS).
PROVIDES PROBABILITY OF PRESENCE/ABSENCE OF RETINAL BIOMARKERS AT A B-SCAN LEVEL IN OCT VOLUMES. THE BIOMARKERS IDENTIFIED ARE:
Fluids (SRF, IRF and Fibrous PED), Hyper reflective Foci (HF), Drusen, Reticular Pseudodrusen (RPD), Epiretinal Membrane (EPM), Geographic Atrophy (GA) and Outer Retinal Atrophy (ORA).
PROVIDES SEGMENTATION OF GA FROM OCT SCANS AND SIMULATION OF ATROPHY PROGRESSION BASED ON VISIT DATA. RESEARCH USE ONLY APPS FOR GEAOGRAPHIC ATROPHY.
GA segmentation on Bscan, en-face GA segmentation in Localiser image, en-face laver information for PR+RR and CS+CC, affected GA area calculation, progression prediction
RetinAI Discovery is a CE-marked medical device according to the Medical Devices Regulation (EU) 2017/745
and the AI models are CE-marked devices according to Medical Devices Directive 93/42/EEC
RetinAI Discovery® is a 510(k) FDA Cleared medical device in US.
RetinAI Discovery® and Retinai® are both trademarks of RetinAI Medical AG.
Discovery and AI Models are CE-Marked medical devices since April 2020 & December 2020 respectively.